Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmune
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Inovio Pharmaceuticals (INO) Bullish Stance Reiterated at Stifel
August 10, 2015 11:34 AM EDTStifel analyst Thomas Shrader reiterated a Buy rating and $19 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the company announced Q2 results and a broad partnership with MedImmune to develop INO-3112 in combination with MedImmunes collection of IO molecules.
Shrader said he likes the deal.... More
Inovio Pharmaceuticals (INO) Overweight Rating, $31 PT Reiterated at Piper Jaffray Amid AstraZeneca Deal
August 10, 2015 11:19 AM EDTPiper Jaffray analyst Charles Duncan reiterated his Overweight rating and $31 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the company announced 2Q financials and a partnership with AstraZeneca worth up to $700M ($27.5M upfront + potential development, regulatory, and commercialization milestones) plus tiered double... More
AstraZeneca's (AZN) MedImmune to Acquire Inovio Pharma's (INO) NO-3112 Immunotherapy Rights
August 10, 2015 6:08 AM EDTInovio Pharma (NASDAQ: INO) announced that it has entered into a license agreement and collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (NYSE: AZN).
Under the agreement, MedImmune will acquire exclusive rights to Inovio's INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which is in phase I/II clinical trials for cervical and head and neck cancers, works by generating killer T-cell responses that are able to destroy HPV 16- and 18-driven tumors. These HPV types are responsible for... More
